0.9094

5.76% 0.0495

After Hours: .94 0.0306 +3.36%

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $0.9094, with a volume of 1.33M. It is up +5.76% in the last 24 hours and up +6.99% over the past month. Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Previous Close:

$0.8599

Open:

$0.88

24h Volume:

1.33M

Relative Volume:

1.69

Market Cap:

$272.37M

Revenue:

$6.23M

Net Income/Loss:

$-95.90M

P/E Ratio:

6.0627

EPS:

0.15

Net Cash Flow:

$-68.47M

1W Performance:

+8.69%

1M Performance:

+6.99%

6M Performance:

-33.13%

1Y Performance:

-19.52%

1-Day Range:

$0.87

$0.94

1-Week Range:

$0.8317

$0.97

52-Week Range:

$0.7739

$1.93

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

202

Twitter

@precigen

Next Earnings Date

2024-11-07

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	0.9094	272.37M	6.23M	-95.90M	-68.47M	0.15
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

Nov 25, 2024

Precigen's SWOT analysis: biotech stock focuses on RRP treatment - Investing.com

Nov 25, 2024

Nov 24, 2024

Precigen Reports Q3 2024 Financial Results - MSN

Nov 24, 2024

Nov 20, 2024

Insiders Sold Precigen Prematurely At US$1.41 With Stock Trading Higher - Simply Wall St

Nov 20, 2024

Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance

Nov 20, 2024

PGEN stock touches 52-week low at $0.78 amid market challenges - Investing.com Canada

Nov 15, 2024

HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN) - MarketBeat

Nov 15, 2024